The recent FDA approval of teclistamab for R/R multiple myeloma

In this video, Bruno Paiva, PhD, University of Navarra, Pamplona, Spain, comments on the recent FDA approval of teclistamab, a bispecific BCMA-directed CD3 T-cell engager, for patients with relapsed/refractory (R/R) multiple myeloma. This interview took place at the 11th International Workshop on Waldenström’s Macroglobulinemia (IWWM-11), held in Madrid, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.